Coverage
-
August 07, 2015
A California federal jury Friday rejected claims by a woman who alleged Eli Lilly & Co. concealed the withdrawal risks of its antidepressant Cymbalta, finding the drugmaker did not mislabel the drug and was not liable for the woman's purported withdrawal symptoms.
3 other articles on this case.
View all »